摘要
目的 :探讨HLA不全相合无血缘供者脐血移植 (UCBT)治疗血液系统恶性肿瘤造血重建、移植相关并发症的发生和生存情况。方法 :对 1例 15岁女性急性非淋巴细胞白血病 (ANLL)患者进行HLA 1个位点不相合2份UCBT。预处理方案 :采用白消安、环磷酰胺 (BU/CTX)方案 ,同时应用抗胸腺细胞球蛋白 (ATG)和Daclizumab(赛尼哌 ,zenapax)。移植物抗宿主病 (GVHD)的预防采用环孢菌素A(CsA)联合短程甲氨蝶呤 (MTX)和霉酚酸酯(MMF)方案。移植有核细胞数 (NC)为 4 .9× 10 7/kg ,CD34+ 细胞为 5 .36× 10 5/kg。结果 :中性粒细胞绝对计数 >0 .5× 10 9/L的时间为移植后第 15天 ;血小板计数 >5 0× 10 9/L的时间为移植后第 37天 ;全血细胞恢复正常的时间为移植后第 4 2天。移植后第 2 1天DNA指纹图提示供者型。受者已无病生存 2 0 0d。结论 :HLA 1个位点不相合的UCBT是可行的 ,对于体重量大的受者 2份脐血移植 (CBT)是可行的。
Objective:To explore the engraftment, Survival and transplantation-related complications of HLA one locus mismatched unrelated umbilical cord blood transplantation for the treatment of hematological malignancies. Method: A 15 years old girl with acute non-lymphoblastic leukemia received two units HLA-mismatched unrelated umbilical cord blood transplantation. The conditioning regimens were BU-CTX plus ATG and daclizumab GVHD prophylaxis regimen consisted of cyclosporine (CsA) and short course methotrexate (MTX) and mycophenolate mofetil (MMF).The patient received 4.9×107nucleated cells/kg, with 5.36×105 CD34+ cells/kg. Result:ANC> 0.5×109/L occurred at day 15, BPC >50×109/L at day 37, the peripheral blood counts normalization at day 42 and the DNA fingerprinting showing engraftment at day 21, The recipient had survived for 200 days. Conclusion: HLA-mismatched unrelated umbilical cord blood transplantation is a feasible procedure to cure a significant proportion of junior with leukemia. Two units of CBT can be used for patients with high weight if the cell number of one unit is not enough.
出处
《临床血液学杂志》
CAS
2004年第4期215-217,共3页
Journal of Clinical Hematology
关键词
白血病
急性
脐血移植
异基因
无血缘
HLA不相合
Leukemia, acute
Cord blood transplantation, heterogenous, unrelated donors
HLA-mismatched